Trials / Completed
CompletedNCT00117871
Study With a Topical Gel to Treat Common Warts in Adults
A Two-Stage, Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 5 Times Per Week for up to 12 Weeks for the Treatment of Common Warts in Adults
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 48 (planned)
- Sponsor
- Graceway Pharmaceuticals, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to evaluate the effectiveness in adults of 2 different strengths of resiquimod gel applied to common wart(s) five times a week for up to 12 weeks. A second purpose is to evaluate the safety of the drug.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Resiquimod |
Timeline
- Start date
- 2004-10-01
- First posted
- 2005-07-11
- Last updated
- 2007-02-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00117871. Inclusion in this directory is not an endorsement.